시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
디지털 게놈 시장 보고서(2025년)
Digital Genome Global Market Report 2025
상품코드 : 1824642
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,546,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,462,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,378,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

디지털 게놈 시장 규모는 향후 수년간 급성장할 것으로 전망됩니다. 2029년에는 CAGR 19.9%를 나타내 966억 5,000만 달러로 성장할 전망입니다. 예측 기간의 성장은 유전성 질환의 유병률 증가, 디지털 게놈에 대한 연구개발 증가, 맞춤형 의료 채용 확대, 생명공학 발전, 만성질환 유병률 증가 등에 기인합니다. 예측 기간의 주요 동향으로는 차세대 시퀀싱기술의 채용 증가, 기술진보 증가, 진단산업에서의 미생물의 광범위한 이용, 개별화의료에 대한 수요 증가, 병원 및 진료소에서의 디지털 게놈 기술의 채용 증가 등을 들 수 있습니다.

향후 5년간의 성장률 19.9%라고 하는 예측은 전회 예측으로부터 0.2%의 소폭의 감소를 반영하고 있습니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향 때문입니다. 관세 장벽은 영국과 한국에서 조달하는 차세대 시퀀싱(NGS) 시스템과 유전체 분석 소프트웨어의 비용을 상승시키고, 맞춤형 의료의 도입을 늦추고, 분자진단의 지출을 증가시킴으로써 미국을 저해할 것으로 예측됩니다. 또한 상호관세와 무역의 긴장과 한계 증가로 인한 세계경제와 무역에 대한 악영향으로 인해 그 영향이 더욱 광범위해질 것으로 보입니다.

유전성 질환의 유병률 증가는 디지털 게놈 시장 전망 성장을 가속할 것으로 예측됩니다. 유전성 질환은 개인의 DNA의 이상이나 돌연변이에 의해 유발되는 유전성 질환으로, 신체의 개발과 기능의 지시를 전달하는 유전 물질입니다. 디지털 게놈 기술은 유전성 질환과 관련된 유전자 돌연변이 및 돌연변이의 확인을 가능하게 합니다. 이 정보는 이러한 질병의 정확하고 조기 진단에 도움이 되며 적시에 개입과 치료를 가능하게합니다. 예를 들어 2023년 8월 미국 의학 도서관인 국립 의학 도서관에 따르면, 겸상 적혈구 빈혈은 미국 아프리카계 미국인의 약 500명 중 한 명이 병을 앓고 있는 유전병입니다. 또한, 아프리카계 미국인의 약 12명 중 1명이 이 질병의 원인이 되는 상염색체 열성 돌연변이를 갖고 있으며, 연간 약 30만명의 유아가 겸상 적혈구 빈혈로 태어나고 있습니다. 따라서 유전성 질환의 유병률 증가는 디지털 게놈 시장 성장을 이끌고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

KTH
영문 목차

영문목차

The digital genome refers to the digitized and organized collection of an organism's genetic material, including its DNA (deoxyribonucleic acid) and RNA (ribonucleic acid) sequences. This digital representation allows for storing, analyzing, and interpreting genetic information using computational tools and technologies. Digital genomes are essential for understanding genetic variations, disease mechanisms, and evolutionary relationships.

The main types of digital genome are sequencing and analyzer instruments, and data analysis and management tools. Sequencing and analyzer instruments refer to equipment used in genomic sequencing and analysis processes, which are essential for decoding the genetic information contained within DNA and RNA molecules. They are used for various applications such as diagnostics, agriculture and animal research, personalized medicine, drug discovery, and treatment analysis by research centers and government institutes, academic institutions, pharmaceutical and biotechnology industries, hospitals, and diagnostic centers.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The main types of digital genome are sequencing and analyzer instruments, and data analysis and management tools. Sequencing and analyzer instruments refer to equipment used in genomic sequencing and analysis processes, which are essential for decoding the genetic information contained within DNA and RNA molecules. They are used for various applications such as diagnostics, agriculture and animal research, personalized medicine, drug discovery, and treatment analysis by research centers and government institutes, academic institutions, pharmaceutical and biotechnology industries, hospitals, and diagnostic centers.

The digital genome market size has grown rapidly in recent years. It will grow from $39.25 billion in 2024 to $46.82 billion in 2025 at a compound annual growth rate (CAGR) of 19.3%. The growth in the historic period can be attributed to growing funding for genomics, reduced cost and high speed of DNA sequencing, entry of new players and start-ups in developing economies, increasing number of drug discoveries, and growing biotech sector.

The digital genome market size is expected to see rapid growth in the next few years. It will grow to $96.65 billion in 2029 at a compound annual growth rate (CAGR) of 19.9%. The growth in the forecast period can be attributed to increasing prevalence of genetic disorders, increasing research and development pertaining to digital genome, growing adoption of personalized medicine, developments in biotechnology, and rising prevalence of chronic diseases. Major trends in the forecast period include the increasing adoption of next-generation sequencing technologies, increasing technological advancements, extensive use of microorganisms in diagnostics industry, increasing demand for personalized medicines, and rising adoption of digital genomic technology by hospitals and clinics.

The forecast of 19.9% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff barriers are expected to hamper the U.S.by increasing the cost of next-generation sequencing (NGS) systems and genomic analysis software sourced from the UK and South Korea, thereby delaying personalized medicine adoption and elevating molecular diagnostics expenditures. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increasing prevalence of genetic disorders is expected to propel the growth of the digital genome market going forward. Genetic disorders are hereditary conditions caused by abnormalities or mutations in an individual's DNA, the genetic material that carries instructions for the development and functioning of the body. Digital genome technologies enable the identification of genetic mutations and variations associated with genetic disorders. This information helps in accurate and early diagnosis of these disorders, allowing for timely intervention and treatment. For instance, in August 2023, according to the National Library of Medicine, a US-based medical library, sickle cell anemia is a genetic disease that affects approximately 1 in 500 African Americans in the United States. Further, about 1 in 12 African Americans carries the autosomal recessive mutation responsible for the disease, and approximately 300,000 infants are born with sickle cell anemia annually. Therefore, the increasing prevalence of genetic disorders is driving the growth of the digital genome market.

Major companies operating in the digital genome market are developing innovative products such as the NovaSeq X Series to understand disease and ultimately transform patient lives. NovaSeq X Series includes the NovaSeq X and NovaSeq X Plus systems, with the NovaSeq X Plus capable of sequencing more than 128 genomes per run and generating more than 20,000 whole genomes per year. For instance, in September 2022, Illumina, Inc., a US-based biotechnology company, launched the NovaSeq X Series, a significant advancement in whole-genome sequencing technology. The system incorporates cost-efficiency throughout the workflow, streamlined informatics, operational simplicity, sustainability advancements, and world-class support. It also enables broader and deeper sequencing, allowing users to scale up any application to include more samples and analyze data more efficiently. The NovaSeq X Series is designed to be the most potent and cost-effective sequencing system, with improved reagent stability and faster data transfers due to optimized genomics data compression. The system was purpose-built for improved sustainability, with a smaller data footprint that reduces storage and energy consumption costs.

In January 2023, Agilent Technologies, a US-based company specializing in analytical solutions, acquired Avida Biomed for an undisclosed amount. This acquisition is aimed at strengthening Agilent Technologies' next-generation sequencing capabilities by incorporating Avida Biomed's target enrichment workflows. Avida Biomed is a US-based life sciences company that specializes in developing advanced target enrichment workflows for next-generation sequencing (NGS).

Major companies operating in the digital genome market are Roche Holding AG, Thermo Fisher Scientific Inc., GE HealthCare Technologies Inc., Quest Diagnostics, Eurofins Scientific SE, Agilent Technologies Inc., Illumina Inc., bioMerieux SA, PerkinElmer Inc., Bio-Rad Laboratories Inc., Qiagen N.V., BGI Genomics, Myriad Genetics Inc., Foundation Medicine Inc., ArcherDx Inc., Invitae Corporation, Oxford Nanopore Technologies Ltd., Luminex Corporation, GenMark Diagnostics Inc., NanoString Technologies Inc., Pacific Biosciences of California Inc., Genewiz, Inscripta Inc., Genomic Health Inc., Becton Dickinson and Company, GenomeMe, Regeneron Pharmaceuticals Inc.

North America was the largest region in the digital genome market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the digital genome market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the digital genome market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The digital genome market consists of revenues earned by entities by providing services such as DNA (deoxyribonucleic acid) and RNA (ribonucleic acid) isolation, profiling, qPCR, next-generation sequencing, and advanced bioinformatics data analysis pipelines. The market value includes the value of related goods sold by the service provider or included within the service offering. The digital genome market also includes sales of sequencing and analyzer instruments, sequencing chips, sample preparation instruments, and sequencing and analysis software. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Digital Genome Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on digital genome market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for digital genome ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The digital genome market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Digital Genome Market Characteristics

3. Digital Genome Market Trends And Strategies

4. Digital Genome Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Digital Genome Growth Analysis And Strategic Analysis Framework

6. Digital Genome Market Segmentation

7. Digital Genome Market Regional And Country Analysis

8. Asia-Pacific Digital Genome Market

9. China Digital Genome Market

10. India Digital Genome Market

11. Japan Digital Genome Market

12. Australia Digital Genome Market

13. Indonesia Digital Genome Market

14. South Korea Digital Genome Market

15. Western Europe Digital Genome Market

16. UK Digital Genome Market

17. Germany Digital Genome Market

18. France Digital Genome Market

19. Italy Digital Genome Market

20. Spain Digital Genome Market

21. Eastern Europe Digital Genome Market

22. Russia Digital Genome Market

23. North America Digital Genome Market

24. USA Digital Genome Market

25. Canada Digital Genome Market

26. South America Digital Genome Market

27. Brazil Digital Genome Market

28. Middle East Digital Genome Market

29. Africa Digital Genome Market

30. Digital Genome Market Competitive Landscape And Company Profiles

31. Digital Genome Market Other Major And Innovative Companies

32. Global Digital Genome Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Digital Genome Market

34. Recent Developments In The Digital Genome Market

35. Digital Genome Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기